Open AccessThe effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly
Author(s) -
Dantong Zhou,
Li Zhang,
Xuke Han,
Yang Gao,
Min Zeng,
Weiwei Yu,
Lisha Sun,
Chen Qiu
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000020750
Subject(s) - medicine , glycemic , diabetes mellitus , type 2 diabetes , randomized controlled trial , clinical trial , inclusion and exclusion criteria , blood sugar , type 2 diabetes mellitus , disease , intensive care medicine , physical therapy , alternative medicine , endocrinology , pathology
Background: Type 2 diabetes is a kind of metabolic disease. Its clinical characteristic is hyperglycemia. Recently, more and more elderly people suffer from type 2 diabetes, and the glycemic variability of the elderly is greater. In addition, blood sugar variation is more likely to cause diabetes complications than simple hyperglycemia. Sancai podwer (SC) is based on the theory of traditional Chinese medicine and gradually formed in the summary of clinical experience. It has the effect of lowering blood sugar and alleviating clinical symptoms of diabetes. But the existing evidence of its efficacy on glycemic variability is insufficient. So, in our study, the randomized controlled trials will be used as a research method to explore the effects of SC on glycemic variability of type 2 diabetes. Method: We will use randomized controlled experiments based on the recommended diagnostic criteria, inclusion and exclusion criteria. A total of 60 elderly patients with type 2 diabetes will be randomly divided into treatment group and control group, 30 cases in each group. The control group will receive conventional western medicine and the intervention group will receive SC combined with western medicine. The standard deviation and coefficient of variation of blood glucose level will be used as evaluation indexes. Discussion: This study can provide evidence for the clinical efficacy and safety of SC in elderly patients with type 2 diabetes mellitus. Trial registration: This study is registered on the Chinese Clinical Trial Registry: ChiCTR2000032611.